Nuvation Bio Inc. (NUVB) Stock
Key stats
- Market cap
- $1.51B
- Price / Earnings ratio
- -10.9x
- EPS (TTM)
- -$0.39
- Volume
- Loading
- 52-week high
- $9.75
- 52-week low
- $3.98
Source: third-party data provider, as of November 13, 2026
Compare with NUVB
Recent news

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
NUVB

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
NUVB

Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
NUVB

Nuvation Bio Q2 Earnings Call Highlights
Nuvation Bio Q2 Earnings Call Highlights
NUVB
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 37.93
- MACD 12/26/9
- -0.25
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.01
- SMA 50
- $5.24
- Price below SMA 50
- EMA 50
- $5.07
- Price below EMA 50
- SMA 200
- $5.34
- Price below SMA 200
- EMA 200
- $5.62
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
NUVB

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
NUVB

Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should Know
NUVB

Nuvation Bio Q2 Earnings Call Highlights
Nuvation Bio Q2 Earnings Call Highlights
NUVB

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
NUVB

4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
NUVB

Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
NUVB

Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?
Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?
NUVB

Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
NUVB

NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug
NUVB
News tone: automated (AI) classification of the article's content, not a price prediction.
About Nuvation Bio Inc.
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David T. Hung M.D. | Founder, President, CEO & Chairman | 1958 |
| Mr. Philippe Pierre Sauvage | CFO & Principal Financial Officer | 1978 |
| Dr. Gary Hattersley Ph.D. | Chief Scientific Officer | 1967 |
| Mr. Moses Makunje CPA | VP of Finance and Principal Accounting & Financial Officer | 1979 |
| Dr. David C. Hanley Ph.D. | Chief Technical Operations Officer | 1970 |
| Robert DeVita | Vice President of Corporate Development & Investor Relations | — |
| Dr. Stephen Dang Ph.D. | Chief Legal Officer & Corporate Secretary | — |
| Ms. Stacy Markel | Chief People Officer | 1965 |
| Ms. Kerry A. Wentworth | Chief Regulatory Officer | 1973 |
| Ms. Colleen Sjogren | Chief Commercial Officer | 1971 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 37.93
- MACD 12/26/9
- -0.25
- EMA 9 of MACD
- -0.26
- MACD histogram
- 0.01
- SMA 50
- $5.24
- Price below SMA 50
- EMA 50
- $5.07
- Price below EMA 50
- SMA 200
- $5.34
- Price below SMA 200
- EMA 200
- $5.62
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $12.60
- High
- $17.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.8 | -3.0 | ||||||||||
| 2022 | -30.9 | -16.6 | +7.6 | -15.3 | -26.8 | -6.9 | -21.6 | +12.4 | -20.3 | -3.1 | -17.7 | -3.0 |
| 2023 | +21.8 | -21.8 | -10.3 | -7.5 | +0.6 | +10.4 | +5.1 | -13.2 | -18.3 | -23.8 | +6.9 | +13.5 |
| 2024 | +3.2 | +16.9 | +63.2 | -19.0 | -3.1 | +7.4 | +21.2 | -9.3 | -23.2 | -3.9 | +26.1 | -10.7 |
| 2025 | -10.8 | -13.2 | -3.3 | +28.6 | -6.6 | -16.7 | +21.6 | +33.2 | +25.4 | +41.1 | +55.3 | +13.7 |
| 2026 | -38.9 | +5.0 | -26.5 | -1.3 | +6.5 | +14.5 | +16.8 | +8.1 | -15.7 | -14.4 | -8.5 |



